World Immunisation Week: Accelerating Global Access to Vaccines in Developing Countries


As Nigeria joins the rest of the world to commemorate the World Immunisation Week, which spans from 24-30 April, with the theme: “Vaccines Work”, Pfizer has expressed her dedication to increasing access to immunisations in countries that carry the greatest proportion of the global burden of pneumococcal disease, which can help prevent diseases and save lives.

In support of this commitment, and to help address the practical constraints experienced by health workers operating in many Gavi countries, Pfizer developed Prevenar 13® in the Multi-Dose Vial-MDV presentation (4 doses per vial). This new presentation will help to significantly reduce storage requirements and shipping costs in communities with health systems that are still developing. In April 2016, the MDV presentation received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). Subsequently, the MDV was pre-qualified by the WHO in July 2016.

COVID-19:Nigeria to Begin Administering 2nd Batch of vaccines Aug. 10

In January 2017, Pfizer launched the new multi-dose vial- MDV which was prequalified in accordance with WHO’s ‘open container policy.’ With its ‘open container’ attributes, it allows for the fourth dose to be used for up to 28 days after the first dose in drawn and providing the recommended cold storage requirements have been met.

To ensure the efficient use of the multi-dose vial, Pfizer is supporting Gavi countries with a refresher training of trainers program on a variety of immunisation topics including the proper handling of multi-dose vials with open container policy. Pfizer partnered  AMP Services, an organisation dedicated to providing the tools to promote preventive medicine and public health worldwide, to execute the training of trainers sessions in 16 countries in 2017.

During the first four months of launch, fifteen countries have received the new MDV and nine of these have completed the training of trainers programs. These training sessions were well received by the national and regional trainers.

WHO Approves Two Highly Effective Ebola Drugs for Immediate Use

“We developed training materials that are easy to use for health workers and allow for interactive learning process at all levels”, said Georgiana Golodnius, Training Project Manager of AMP Services. In the countries where we have implemented training of the trainers, 97.3% of the participants think the developed training tools are useful and relevant.”

“Indeed we learnt a lot from the training and I feel the knowledge gained will be used to train other health workers in the country” Mr Mwagomba, Malawi.

Pfizer is committed to constant innovation and development to ensure that the challenges facing many throughout the world- geographical, economical and operational- can and will be met



Pfizer Inc.: Working together for a healthier world®

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world’s best-known consumer healthcare products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us.



Please enter your comment!
Please enter your name here